AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-03-04 pm EST 5-day change 1st Jan Change
177 USD -1.04% Intraday chart for AbbVie Inc. -0.98% +14.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Abbvie Insider Sold Shares Worth $1,754,555, According to a Recent SEC Filing MT
Abbvie Insider Sold Shares Worth $12,153,957, According to a Recent SEC Filing MT
Abbvie Insider Sold Shares Worth $908,688, According to a Recent SEC Filing MT
Abbvie Insider Sold Shares Worth $2,509,002, According to a Recent SEC Filing MT
AbbVie Secures Rights to OSE Immunotherapeutics' Drug Candidate MT
OSE Immuno: share price soars following partnership with AbbVie CF
OSE Immunotherapeutics, AbbVie Partner on Chronic Inflammation Monoclonal Antibody MT
Global markets live: Chevron, Expedia, Standard Chartered, Broadcom, Meta Platforms... Our Logo
AbbVie, Genmab Lymphoma Treatment Receives Priority Review by FDA for New Indication MT
AbbVie, Genmab Get Speedy FDA Review of Epkinly in Follicular Lymphoma DJ
Genmab, AbbVie Secure US FDA's Priority Review Tag for Blood Cancer Therapy MT
Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma CI
J&J: FDA approves new formulation of Imbruvica CF
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs... Our Logo
How long will this bullish phase last? Our Logo
Alvotech Shares Rise Premarket After Humira Biosimilar Approval DJ
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
Abbvie Insider Sold Shares Worth $9,184,048, According to a Recent SEC Filing MT
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS... Our Logo
Sector Update: Health Care Stocks Gain Late Afternoon MT
AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions MT
AbbVie Ties Up With Tentarix to Develop New Drugs for Oncology, Immunology MT
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls MT
Phew! The party continues! Our Logo
Abbvie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology CI
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
177 USD
Average target price
180.7 USD
Spread / Average Target
+2.09%
Consensus
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse
  4. News AbbVie Inc.
  5. Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW